Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
about
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetesA novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP.Acetylated α-Tubulin Regulated by N-Acetyl-Seryl-Aspartyl-Lysyl-Proline(Ac-SDKP) Exerts the Anti-fibrotic Effect in Rat Lung Fibrosis Induced by SilicaDiabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis.Pathophysiology of the aging kidney and therapeutic interventions.Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease.The biological consequence of obesity on the kidney.Potential approaches to reverse or repair renal fibrosis.The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney FibrosisN-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.Kinetics of mushroom tyrosinase and melanogenesis inhibition by N-acetyl-pentapeptides.
P2860
Q27008887-30C6D3C8-C3E1-4EB9-BFEE-35268760475AQ35088357-E2DB7BBA-3483-4A26-A0AE-F388EF284FBBQ36117802-33DAC670-1AB9-49E5-B611-A8F898F2AC9CQ36589609-0B3D9B60-6E90-43BE-9B6D-8B3B944DE4DAQ38053074-B3EA85E5-0964-4E1C-987C-EDBECD8C6A63Q38083596-8FA72831-F944-497C-9DA9-559A1C8142F9Q38112518-A2A460EB-91D8-4195-9459-D876D0711E27Q38186986-812DEEBD-AFEB-49AB-8197-8BA2394CB5A9Q38224257-081D6BDC-73F8-40C8-9B8E-B7D024B179C6Q39816079-BF4B4984-F24F-4EDF-AE34-38C927F731A7Q41832445-30DDAB3C-0B13-4B63-9155-D287245CBF06Q42116033-E1A94533-896A-42E2-9655-639064925196Q55652960-92C51EA3-6568-4168-9002-FBBEAE114136
P2860
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Elevation of the antifibrotic ...... I-converting enzyme inhibitors
@en
Elevation of the antifibrotic ...... -converting enzyme inhibitors.
@nl
type
label
Elevation of the antifibrotic ...... I-converting enzyme inhibitors
@en
Elevation of the antifibrotic ...... -converting enzyme inhibitors.
@nl
prefLabel
Elevation of the antifibrotic ...... I-converting enzyme inhibitors
@en
Elevation of the antifibrotic ...... -converting enzyme inhibitors.
@nl
P2093
P2860
P356
P1476
Elevation of the antifibrotic ...... I-converting enzyme inhibitors
@en
P2093
Daisuke Koya
Keizo Kanasaki
Megumi Kanasaki
Munehiro Kitada
Takako Nagai
P2860
P2888
P356
10.1186/1755-1536-4-25
P577
2011-11-30T00:00:00Z
P5875
P6179
1030117564